Serum Concentrations of IGF-1R, ERK2, and EGFR and Their Clinical Significance in Patients with Neuroendocrine Tumors
Source abstract
Abstract
Neuroendocrine tumors are a heterogeneous group of tumors located mainly in the gastrointestinal tract or the respiratory system. We aimed to determine the concentrations of IGF-1R, ERK2, and EGFR using the ELISA method in serum samples from patients with NETs and from a control group. Results were evaluated with the selected demographic, clinicopathological, and biochemical characteristics. The analyses performed on a group of patients (80 in the study group and 62 in the control group) showed that the concentration of EGFR in patients with neuroendocrine tumors was significantly higher (p < 0.001) compared to the control group. Additionally, a significantly higher (p < 0.001) EGFR concentration was found in GEP-NET. Our results indicate that impaired EGFR signaling pathways are important in the context of neuroendocrine tumors. The data presented are a good starting point for further analysis of these proteins.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Neuroendocrine Tumor Research Advances · Neuroblastoma Research and Treatments · Lung Cancer Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana St., 41-808 Zabrze, Poland
Department of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 35 Ceglana St., 40-514 Katowice, Poland
Department of Medical Statistics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 30 Ostrogórska St., 40-055 Katowice, Poland
Funding
Medical University of Silesia
References (91)
Show source-provided references
1. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin10.1677/ERC-09-0108 ↗
2. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)10.5603/EP.a2022.0049 ↗
3. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement10.1177/0004563215613109 ↗
4. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs)10.1097/MPA.0b013e318271c0d5 ↗
5. Sansone, A., Lauretta, R., Vottari, S., Chiefari, A., Barnabei, A., Romanelli, F., and Appetecchia, M. (2019). Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers, 11.10.3390/cancers11081113 ↗
6. Clinicopathologic characteristics of neuroendocrine tumors with assessment by digital image analysis for Ki-67 index with a focus on the gastroenteropancreatic tract: A single-center study
7. Established and novel circulating neuroendocrine tumor biomarkers for diagnostic, predictive and prognostic use10.1016/j.beem.2023.101785 ↗
8. Oncogenic Fusion Proteins Adopt the Insulin-Like Growth Factor Signaling Pathway10.1186/s12943-018-0807-z ↗
9. Cevenini, A., Orrù, S., Mancini, A., Alfieri, A., Buono, P., and Imperlini, E. (2018). Molecular Signatures of the Insulin-Like Growth Factor 1-Mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers. Int. J. Mol. Sci., 19.10.3390/ijms19082411 ↗
10. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy10.1080/13543784.2019.1694660 ↗
11. Motylewska, E., Braun, M., Kazimierczuk, Z., Ławnicka, H., and Stępień, H. (2020). IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms. Pharmaceuticals, 13.10.3390/ph13110354 ↗
12. Lamberti, G., Brighi, N., Maggio, I., Manuzzi, L., Peterle, C., Ambrosini, V., Ricci, C., Casadei, R., and Campana, D. (2018). The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. Int. J. Mol. Sci., 19.10.3390/ijms19030747 ↗
13. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism10.1038/sj.onc.1209990 ↗
14. ERK/MAPK signalling pathway and tumorigenesis
15. FOXA1 inhibits prostate cancer neuroendocrine differentiation10.1038/onc.2017.50 ↗
16. Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression10.1007/s00432-022-04061-7 ↗
17. Uribe, M.L., Marrocco, I., and Yarden, Y. (2021). EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 13.10.3390/cancers13112748 ↗
18. Emerging functions of the EGFR in cancer10.1002/1878-0261.12155 ↗
19. Li, X., Zhao, L., Chen, C., Nie, J., and Jiao, B. (2022). Can EGFR be a therapeutic target in breast cancer?. Biochim. Biophys. Acta Rev. Cancer, 1877.10.1016/j.bbcan.2022.188789 ↗
20. Cell signalling by receptor tyrosine kinases10.1016/S0092-8674(00)00114-8 ↗
21. Zanini, S., Renzi, S., Giovinazzo, F., and Bermano, G. (2020). mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Front. Endocrinol., 11.10.3389/fendo.2020.562505 ↗
22. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors10.1530/ERC-15-0002 ↗
23. Jin, X.-F., Spöttl, G., Maurer, J., Nölting, S., and Auernhammer, C.J. (2020). Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects. Cancers, 12.10.3390/cancers12020345 ↗
24. Evaluation of EGF, EGFR, and E-cadherin as potential biomarkers for gastrointestinal cancers10.1016/j.flm.2017.08.001 ↗
25. EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms10.1002/ijc.34499 ↗
26. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States10.1200/JCO.2007.15.4377 ↗
27. Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms10.23736/S2724-6507.23.04140-4 ↗
28. Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?10.1016/j.beem.2023.101836 ↗
29. Targeting receptor tyrosine kinases in neuroendocrine neoplasm: What’s going on with lung carcinoids?10.23736/S2724-6507.22.03879-9 ↗
30. Targeting the mTOR signaling network for cancer therapy10.1200/JCO.2008.20.0766 ↗
31. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors10.1126/science.1200609 ↗
32. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors10.1158/1078-0432.CCR-11-2123 ↗
33. Everolimus for advanced pancreatic neuroendocrine tumors10.1056/NEJMoa1009290 ↗
34. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells
35. IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells10.1111/jcmm.12473 ↗
36. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours10.1677/erc.1.01090 ↗
37. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3’-kinase-Akt signaling pathways
38. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
39. Elevated serum concentrations of IGF-1 and IGF-1R in patients with thyroid cancers10.5507/bp.2019.018 ↗
40. Manzella, L., Massimino, M., Stella, S., Tirrò, E., Pennisi, M.S., Martorana, F., Motta, G., Vitale, S.R., Puma, A., and Romano, C. (2019). Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment. Int. J. Mol. Sci., 20.10.3390/ijms20133258 ↗
41. Zhong, W., Wang, X., Wang, Y., Sun, G., Zhang, J., and Li, Z. (2023). Obesity and endocrine-related cancer: The important role of IGF-1. Front. Endocrinol., 14.10.3389/fendo.2023.1093257 ↗
42. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination10.1038/onc.2013.460 ↗
43. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide10.18632/oncotarget.5631 ↗
44. IGF-1R expression in localized cervical carcinoma patients treated by radiochemotherapy10.1016/j.ygyno.2007.04.004 ↗
45. IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer10.1093/carcin/bgv053 ↗
46. Insulin-like growth factor-1 receptor knockdown enhances radiosensitivity via the HIF-1α pathway and attenuates ATM/H2AX/53BP1 DNA repair activation in human lung squamous carcinoma cells
47. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: An opportunity to increase the efficacy of standard therapy10.1158/1535-7163.MCT-12-1067 ↗
48. IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer
49. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma10.1002/cncr.26661 ↗
50. Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment10.1186/s13058-018-1063-2 ↗
51. Revisiting the IGF-1R as a breast cancer target10.1038/s41698-017-0017-y ↗
52. The role of the insulin-like growth factor-1 system in breast cancer10.1186/s12943-015-0291-7 ↗
53. Lee, J.S., Tocheny, C.E., and Shaw, L.M. (2022). The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target. Life, 12.10.3390/life12121992 ↗
54. IGF-1R targeting in cancer–does sub-cellular localization matter?10.1186/s13046-023-02850-7 ↗
55. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer10.1002/ijc.32668 ↗
56. The interplay between IGF-1R signaling and Hippo-YAP in breast cancer stem cells10.1186/s12964-023-01088-2 ↗
57. Vantaggiato, C., Formentini, I., Bondanza, A., Bonini, C., Naldini, L., and Brambilla, R. (2006). ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J. Biol., 5.10.1186/jbiol38 ↗
58. The JAK/STAT signaling pathway: From bench to clinic10.1038/s41392-021-00791-1 ↗
59. Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels10.1128/MCB.00800-07 ↗
60. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target10.1159/000100508 ↗
61. Gastrointestinal neuroendocrine tumors in 202010.4251/wjgo.v12.i8.791 ↗
62. Phosphorylation of Rap1 by cAMP-dependent Protein Kinase (PKA) Creates a Binding Site for KSR to Sustain ERK Activation by cAMP10.1074/jbc.M116.768986 ↗
63. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology10.1016/j.jcmgh.2014.12.008 ↗
64. Gastroenteropancreatic neuroendocrine tumours10.1016/S1470-2045(07)70410-2 ↗
65. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: Attractive targets for molecular-oriented therapy10.1517/14728222.2011.541440 ↗
66. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells10.1038/onc.2010.240 ↗
67. EGFR-TKIs resistance via EGFR-independent signaling pathways10.1186/s12943-018-0793-1 ↗
68. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients10.1186/bcr2149 ↗
69. Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer10.1002/1878-0261.13500 ↗
70. Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases10.3390/receptors3020008 ↗
71. Epidermal growth factor receptor expression and activation in neuroendocrine tumours10.1111/j.1365-2826.2006.01425.x ↗
72. McClellan, K., Chen, E.Y., Kardosh, A., Lopez, C.D., Del Rivero, J., Mallak, N., Rocha, F.G., Koethe, Y., Pommier, R., and Mittra, E. (2022). Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 14.10.3390/cancers14194769 ↗
73. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives10.1038/s41392-021-00572-w ↗
74. Clinical significance of serum epidermal growth factor receptor (EGFR) concentrations in patients with breast cancer10.1016/j.cyto.2014.09.001 ↗
75. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients10.1186/bcr1788 ↗
76. Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells10.1002/cnr2.2049 ↗
77. Kjær, I.M., Olsen, D.A., Brandslund, I., Bechmann, T., Jakobsen, E.H., Bogh, S.B., and Madsen, J.S. (2020). Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer. Sci. Rep., 10.10.1038/s41598-020-72944-1 ↗
78. Banys-Paluchowski, M., Witzel, I., Riethdorf, S., Rack, B., Janni, W., Fasching, P.A., Solomayer, E.F., Aktas, B., Kasimir-Bauer, S., and Pantel, K. (2017). Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. Sci. Rep., 7.10.1038/s41598-017-17514-8 ↗
79. Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis10.4103/2303-9027.117692 ↗
80. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes10.1200/JCO.18.01585 ↗
81. Evangelou, G., Vamvakaris, I., Papafili, A., Anagnostakis, M., and Peppa, M. (2024). Lung NETs and GEPNETs: One Cancer with Different Origins or Two Distinct Cancers?. Cancers, 16.10.20944/preprints202402.0609.v1 ↗
82. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors10.1007/s13277-015-4114-7 ↗
83. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future10.5306/wjco.v12.i4.217 ↗
84. O’leary, C., Gasper, H., Sahin, K.B., Tang, M., Kulasinghe, A., Adams, M.N., Richard, D.J., and O’byrne, K.J. (2020). Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals, 13.10.3390/ph13100273 ↗
85. Gou, Q., Gou, Q., Gan, X., and Xie, Y. (2024). Novel therapeutic strategies for rare mutations in non-small cell lung cancer. Sci. Rep., 14.10.1038/s41598-024-61087-2 ↗
86. Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study10.4143/crt.2023.493 ↗
87. Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers10.1038/s41467-024-46284-x ↗
88. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?10.1080/14728222.2023.2218613 ↗
89. Friedlaender, A., Perol, M., Banna, G.L., Parikh, K., and Addeo, A. (2024). Oncogenic alterations in advanced NSCLC: A molecular super-highway. Biomark. Res., 12.10.1186/s40364-024-00566-0 ↗
90. Hernandez-Rienda, L., Del Olmo-García, M.I., and Merino-Torres, J.F. (2022). Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives. Metabolites, 12.10.3390/metabo12111103 ↗
91. NIKE Group. Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?10.1016/j.ctrv.2018.04.013 ↗